论文部分内容阅读
目的：研究静脉输注悉能（硫酸依替米星）在呼吸道感染患者体内的药代动力学。方法：采用微生物法测定了１０例呼吸道感染患者静脉滴注２００ｍｇ悉能的血、尿及痰中药物浓度，并进行药代动力学研究。结果与结论：该药在呼吸道感染患者体内最高血药浓度为１４．７４μｇ／ｍｌ，１２ｈ仍维持在０．２９μｇ／ｍｌ。经ＰＫＢＰ－Ｎ１药代动力学程序拟合符合二室开放动力学模型，其参数为Ｔ１／２α＝０．２５７ｈ，Ｔ１／２β＝２．２２ｈ，Ｖｃ＝３４．３２Ｌ，Ｋ２１＝２．１４ｈ～（－１），Ｋｌ２＝０．４８ｈ～（－１），Ｋ１０＝０．３９ｈ～（－１）。１２ｈ肾排泄累积百分比为２１．３７％，Ｋｅ＝０．０２７ｈ～（－１），Ｋ＝０．４３１ｈ～（－１）。痰中药物浓度在滴注结束后２ｈ达到最高值，即 ２．０９μｇ／ｍｌ。
OBJECTIVE: To study the pharmacokinetics of intravenous infusion of cetuximab (etimicin sulfate) in patients with respiratory tract infections. Methods: The concentrations of 200mg Xunneng blood, urine and sputum in 10 patients with respiratory tract infection were measured by the microbiological method and the pharmacokinetics were studied. RESULTS AND CONCLUSION: The drug had the highest serum concentration of 14.74μg / ml in patients with respiratory tract infection and remained at 0.29μg / ml in 12h. The PKBP-N1 pharmacokinetic program fitted the two-compartment open kinetic model and the parameters were T1 / 2α = 0.257h, T1 / 2β = 2.22h, Vc = 34.32L, K21 = 2.14h ~ (-1), Kl2 = 0.48h ~ (-1), K10 = 0.39h ~ (-1). The cumulative percentage of renal excretion at 12h was 21.37%, Ke = 0.027h ~ (-1) and K = 0.431h ~ (-1). The concentration of drug in sputum reached the highest value at 2h after the instillation, that is 2.09μg / ml.